Learning from “Learning from Hackers”

Alongside colleagues (Enrico Coiera and Richard Day) from here in Sydney and (Kenneth Mandl) from near Boston in the US, I wrote an article for Science Translational Medicine in which we related the current system of “clinical trial evidence translation” to the very successful open source software movement. We highlighted the factors in that success - … Continue reading Learning from “Learning from Hackers”

Repost: Pharma’s influence over published clinical evidence

Below is a copy of an article I wrote for The Conversation. It’s an independent source of information and analysis about things that matter - but from the university and research perspective, which means it’s generally more rigorous than much of the rest. This article was originally published at The Conversation. Read the original article.   TRANSPARENCY … Continue reading Repost: Pharma’s influence over published clinical evidence

Who creates the clinical evidence for cholesterol-lowering drugs?

Last week the US Food and Drug Administration released new warnings about the use of statins for patients in the United States. The warnings that have been added to labels in the US come from worries about liver injury, memory-loss and confusion, increased blood sugar levels and some new potentially dangerous interactions between one statin … Continue reading Who creates the clinical evidence for cholesterol-lowering drugs?

Do pharmaceutical companies have too much influence over the evidence base?

Imagine you are a doctor and you have a patient sitting with you in your office. You have already diagnosed your patient with a condition. Treatment for this condition will definitely include prescribing the patient with one or more drugs. And, because the condition is quite common, there are several government-subsidised drugs from which you … Continue reading Do pharmaceutical companies have too much influence over the evidence base?